首页> 美国卫生研究院文献>Internal Medicine >Outpatient 131I Treatment for a Patient with Graves Disease Receiving Hemodialysis
【2h】

Outpatient 131I Treatment for a Patient with Graves Disease Receiving Hemodialysis

机译:Graves病接受血液透析患者的门诊131I治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A patient presented with hyperthyroidism and end-stage renal disease requiring hemodialysis that was difficult to control despite increased dosages of anti-thyroid drugs. The condition could finally be controlled by 131I radioactive iodine therapy (RIT) and hemodialysis provided under a hospital-linkage system. During three hemodialysis sessions after the oral administration of 131I, we measured the radioactivity released from the patient and the radioactivity of the devices/tools used. The radioactivity of the devices/tools was managed by allowing the isotope to decay into non-radioactive elements. Our experience suggests that outpatient RIT may provide a safe and convenient means of treating Graves' disease, even in patients receiving hemodialysis.
机译:一名患有甲状腺功能亢进症和终末期肾脏疾病的患者需要进行血液透析,尽管抗甲状腺药物的剂量增加,但仍难以控制。该病最终可以通过医院链接系统提供的 131 I放射性碘疗法(RIT)和血液透析来控制。在口服 131 I后的三个血液透析期间,我们测量了患者释放的放射性以及所用设备/工具的放射性。通过允许同位素分解成非放射性元素来管理设备/工具的放射性。我们的经验表明,即使在接受血液透析的患者中,门诊RIT也可能提供一种安全便捷的方法来治疗Graves病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号